Posted by Michael Wonder on 01 Apr 2020
Rhythm Pharmaceuticals completes rolling submission of new drug application to U.S. FDA for setmelanotide in POMC and LEPR deficiency obesities
30 March 2020 - Rhythm Pharmaceuticals today announced that it has completed its rolling submission of a new drug application to the U.S. FDA for setmelanotide for the treatment of pro-opiomelanocortin deficiency obesity and leptin receptor deficiency obesity.
Rhythm has requested priority review for the application which, if granted, could provide a target FDA review period of six months from the application filing date.
